MARKET

CERC

CERC

Cerecor
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.140
-0.110
-4.89%
Closed 16:05 04/02 EDT
OPEN
2.270
PREV CLOSE
2.250
HIGH
2.287
LOW
2.030
VOLUME
117.26K
TURNOVER
--
52 WEEK HIGH
6.23
52 WEEK LOW
1.520
MARKET CAP
123.28M
P/E (TTM)
-5.6390
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CERC stock price target is 11.00 with a high estimate of 12.00 and a low estimate of 10.00.

EPS

CERC News

More
  • Aytu: A One-Trick Play
  • Seeking Alpha - Article · 2d ago
  • Big Stock Buys at Winnebago, National CineMedia
  • Barrons.com · 6d ago
  • The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Xencor Licenses Tech To Vir For COVID-19 Treatment, Delay In Pfizer's Upjohn-Mylan Merger
  • Benzinga · 03/26 13:23
  • Cerecor up 29% on exploratory work in COVID-19
  • Seeking Alpha - Article · 03/26 11:36

Industry

Biotechnology & Medical Research
+3.33%
Pharmaceuticals & Medical Research
+2.80%

Hot Stocks

Symbol
Price
%Change

About CERC

Cerecor, Inc. is a biopharmaceutical company. The Company is focused on development and commercialization of treatments for pediatric and orphan diseases. Its pediatric rare disease pipeline is led by CERC-801, CERC-802 and CERC-803 (CERC-800 programs), which are therapies for inborn errors of metabolism, specifically disorders known as Congenital Disorders of Glycosylation (CDGs). The Company is also developing CERC-002, CERC-006 and CERC-007. CERC-007 is an anti-IL-18 monoclonal antibody which is developed for autoimmune inflammatory diseases such as Adult Onset Stills Disease (AOSD) and Multiple Myeloma. CERC-006 is an mTORC1/2 inhibitor which is developed as a treatment for Lymphatic Malformations (LM). CERC-002 is an anti-LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for HVEM, a receptor expressed by T lymphocytes), monoclonal antibody is developed as a treatment for Pediatric Crohn's Disease.
More

Webull offers kinds of Cerecor Inc stock information, including NASDAQ:CERC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CERC stock news, and many more online research tools to help you make informed decisions.